Data Sheet 1_Cost-effectiveness of first-line aumolertinib versus osimertinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer in China.docx

Outcomes included total costs, quality-adjusted life-years (QALYs), and incremental net monetary benefit (iNMB) at a willingness-to-pay threshold of 298,995 Chinese Yuan (CNY) per QALY. One-way sensitivity, probabilistic sensitivity, scenario, threshold, and exploratory subgroup analyses were performed.</p>Results<p>In the overall population, osimertinib was associated with a total cost of 193,447.40 CNY and 1.981 QALYs, whereas aumolertinib was associated with a total cost of 207,484.66 CNY and 2.000 QALYs.

Compared with osimertinib, aumolertinib yielded an additional 0.019 QALYs at an additional cost of 14,037.26 CNY, resulting in an iNMB of −8,307.60 CNY. Thus, aumolertinib was not economically favorable in the base-case analysis. At the prespecified threshold, the probability of being cost-effective was 0.58 for osimertinib and 0.42 for aumolertinib.

Scenario and threshold analyses showed that the results were sensitive to drug price and the comparative OS effect. Exploratory subgroup analyses showed differences in the direction of point estimates across subgroups, but uncertainty remained substantial across all subgroups.</p>Conclusion<p>Under the current Chinese pricing environment and available indirect comparative evidence, aumolertinib and osimertinib showed broadly similar economic profiles as first-line treatment for advanced EGFR-mutated NSCLC.</p>